M
Martin C. Müller
Researcher at Heidelberg University
Publications - 179
Citations - 14792
Martin C. Müller is an academic researcher from Heidelberg University. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 54, co-authored 178 publications receiving 13711 citations. Previous affiliations of Martin C. Müller include University Hospital Heidelberg & Medical University of Graz.
Papers
More filters
Journal ArticleDOI
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Andreas Hochhaus,Michele Baccarani,Michael W. Deininger,Jane F. Apperley,Jeffrey H. Lipton,Stuart L. Goldberg,S. Corm,Neil P. Shah,Francisco Cervantes,Richard T. Silver,Dietger Niederwieser,Richard Stone,Hervé Dombret,Richard A. Larson,Lydia Roy,Timothy P. Hughes,Martin C. Müller,Rana Ezzeddine,A. Countouriotis,Hagop M. Kantarjian +19 more
TL;DR: Dasatinib is associated with high response rates in patients with imatinib-resistant or -intolerant CP-CML, and it is shown that this drug is effective for patients with chronic myelogenous leukemia resistant or intolerant toImatinib.
Journal ArticleDOI
Standardized definitions of molecular response in chronic myeloid leukemia
TL;DR: A framework within which standardization of MR can be taken forward is proposed, critical that the measurement of MR is standardized in a manner to withstand both intra- and inter-laboratory variability, as well as new methodological developments.
Journal ArticleDOI
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Müller,Jorge E. Cortes,Dong-Wook Kim,Brian J. Druker,Philipp Erben,Ricardo Pasquini,Susan Branford,Timothy P. Hughes,Jerald P. Radich,Lynn Marie Ploughman,Jaydip Mukhopadhyay,Andreas Hochhaus,Andreas Hochhaus +12 more
TL;DR: Overall, dasatinib has durable efficacy in patients with or without BCR-ABL mutations, including highly imatinib-resistant mutations in the P-loop region.
Journal ArticleDOI
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Nicholas C.P. Cross,Helen E. White,Dolors Colomer,Hans Ehrencrona,Letizia Foroni,Enrico Gottardi,Thoralf Lange,Thomas Lion,K Machova Polakova,Stéphanie Dulucq,Giovanni Martinelli,E. Oppliger Leibundgut,Niels Pallisgaard,Gisela Barbany,Tomasz Sacha,Rodica Talmaci,Barbara Izzo,Giuseppe Saglio,Fabrizio Pane,Martin C. Müller,Andreas Hochhaus +20 more
TL;DR: Detailed laboratory recommendations are presented to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Journal ArticleDOI
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Rüdiger Hehlmann,Martin C. Müller,Michael Lauseker,Benjamin Hanfstein,Alice Fabarius,Annette Schreiber,Ulrike Proetel,Nadine Pletsch,Markus Pfirrmann,Claudia Haferlach,Susanne Schnittger,H. Einsele,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Gerhard Ehninger,Dominik Heim,Hermann Heimpel,Christoph Nerl,Stefan W. Krause,Dieter K. Hossfeld,Hans-Jochem Kolb,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +31 more
TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.